Dr. Debu Tripathy, editor-in-chief of CURE journalThough developments in therapies for small cell lung most cancers (SCLC) are scarce for this aggressive most...
Adcetris Plus Revlimid and Rituxan Continues to Enhance Relapsed/Refractory Diffuse Giant B-Cell Lymphoma OutcomesIncluding Adcetris (brentuximab vedotin) to Revlimid (lenalidomide) and Rituxan (rituximab)...
First-Line Rybrevant Plus Lazcluze Exhibits Development Towards Total Survival in EGFR-Optimistic NSCLCWithin the first line of therapy, Rybrevant (amivantamab) plus Lazcluze (lazertinib) demonstrated...
Pictures by Jill StifflerFor Sabrina Potts, the approval by the Meals and Drug Administration (FDA) of Imdelltra (tarlatamab-dlle) in Could 2024 for the...
